Tue Apr 16, 2013 9:06am EDT (Reuters) - Eli Lilly and Co said two additional late-stage studies evaluating its experimental diabetes drug dulaglutide met the main goal of minimizing hemoglobin A1c levels, a measure of blood sugar. Along with good results from three other late-stage studies introduced in October, a marketing application will be supported by the data for dulaglutide, Lilly said in a record. In the study called AWARD 2, the company explained a mg dose of its medicine proved more advanced than Sanofi's Lantus, at 52 weeks in type 2 diabetes patients, that are already on two different diabetes medications, metformin and glimeperide. Dulaglutide also trumped insulin lispro, in combination with Lantus, at 26 days of therapy in research dubbed as AWARD 4, Lilly said. The business said the most frequently reported adverse events were intestinal. In October, Lilly reported positive results of the other three studies where dulaglutide was compared with other diabetes medications. Lilly's stocks closed at $56.49 on Monday on the Newest York Stock Exchange. (Revealing By Pallavi Ail in Bangalore; Editing by Supriya Kurane)
No comments:
Post a Comment